Keywords: bayer/onyx, nexavar, boosts, os, hcc, patients, who

Bayer/Onyx' Nexavar boosts OS 44% in HCC

Article | 10 November 2008

Print This

Patients who took the liver cancer drug Nexavar (sorafenib) saw a large improvement in overall survival compared to those on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in